Pemirolast (potassium)

Pemirolast potassium is an orally active antiallergic agent. Pemirolast potassium attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast potassium can be used for bronchial asthma and conjunctivitis research[1]-[5].

Product Specifications

CAS Number

[100299-08-9]

Product Name Alternative

TWT-8152; BMY 26517

UNSPSC

12352005

Hazard Statement

H302

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Pemirolast-potassium.html

Purity

99.99

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[K+]

Molecular Formula

C10H7KN6O

Molecular Weight

266.30

Precautions

H302

References & Citations

[1]Kawashima T, et al. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol. 1994;103 (4) :405-9. |[2]Yanni JM, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997 Dec;79 (6) :541-5.|[3]Fujimiya H, et al. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turnover. Int Arch Allergy Appl Immunol. 1991;96 (1) :62-7.|[4]Itoh Y, et al. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology. 2004 May;46 (6) :888-94. |[5]Tatsushima Y, et al. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661 (1-3) :57-62.